author-photo

Svea K. Wahlstrom

AstraZeneca

5

Papers

2

Citations

Citation Trend

Filter By

Papers (3) Sort By

Journal Conference Others

Time and Personnel Costs Associated with Adverse Event (AE) Management Among Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Acalabrutinib, Ibrutinib, or Venetoclax

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Patient and physician decision-making on the use of novel agents in chronic lymphocytic leukemia (CLL): What drives preferences?

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
How Do Progression-Free Survival and Toxicity Risks Influence Oncologist and Patient Preferences for Novel Agents in Chronic Lymphocytic Leukemia?

2020 Blood
Show All
- Source
- Cite
- Save
Citations (0)